NRX Pharmaceuticals

NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. It engages in developing of novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded on September 18, 2017 and is headquartered in Wilmington, DE.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

NRx Pharmaceuticals reports strong Q1 performance and growth opportunities

NRx Pharmaceuticals made strides in innovation, debt reduction, and financial stability in Q1 2024.
The company's focus on mental health treatments and addressing unmet medical needs shows market relevance.
Challenges include resolving short interest concerns and securing FDA approvals for key drugs.
Opportunities lie in out-licensing, revenue generation, and partnerships for growth and market expansion.

NRx Pharmaceuticals reports progress in financials and scientific breakthroughs

NRx Pharmaceuticals showcased financial and scientific progress, positioning itself for growth and market penetration.
Strategic initiatives like clinic roll-up and commercial targeting demonstrate a proactive approach to market challenges.
While facing transitions and competition, NRx Pharmaceuticals has opportunities for expansion and innovation in psychiatric treatments.
The company's focus on financial stability, product development, and market strategies reflects a comprehensive growth strategy.

NRx Pharmaceuticals reports improved financials and plans for growth

NRx Pharmaceuticals demonstrated improved financial performance and strategic planning in Q3 2024, with reduced losses and enhanced operational efficiency.
The company's focus on innovation, acquisitions, and precision psychiatry clinics highlights a commitment to growth and market leadership.
While facing challenges in revenue recognition and clinic valuations, NRx Pharmaceuticals has opportunities to drive revenue growth and expand its market presence.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NRX Pharmaceuticals (NRXP) stock is surging higher on Thursday thanks to recent results from a clinical trial of its Covid-19 treatment. The post NRXP Stock: The Critical Covid-19 Trial Results That Have NRx Pharma Rocketing Higher appeared first on InvestorPlace.

NRXP Stock: The Critical Covid-19 Trial Results That Have NRx Pharma Rocketing Higher

Shares of NRx Pharmaceuticals Inc. NRXP, -13.55% soared 39.9% in premarket trading on Thursday after the company said new peer-reviewed data published in the Journal of Infectious Diseases and Treatment showed that its experimental COVID-19 therapy improved survival in critically ill patients. The data came from an open-label trial assessing respiratory failure in 21 patients who were too sick to participate in the company's Phase 2b/3 trial evaluating the drug, aviptadil, in COVID-19 patients with respiratory failure.

NRx shares jump 39% on new clinical data testing its experimental COVID-19 drug in the critically ill

RADNOR, Pa., Oct. 14, 2021 /PRNewswire/ -- NRx Pharmaceuticals (Nasdaq: NRXP), today announced the publication of peer-reviewed results from a prospective, open-label, administratively controlled trial of aviptadil for the treatment of respiratory failure in patients with Critical COVID-19.

Journal of Infectious Diseases and Treatment Publishes Positive Trial Data of Aviptadil in High Comorbidity Patients Suffering from Critical COVID-19 with Respiratory Failure

Shares of NRX Pharmaceuticals Inc. (NASDAQ: NRXP) spiked in price by over 60% on Tuesday due to positive news from the FDA related to their product Zyesami. This could be the return of their shares after a 65% fall over the past 6 months.

Are the shares of NRX Pharma making a comeback? A look at the charts

The stock price of NRx Pharmaceuticals Inc (NASDAQ: NRXP) increased by over 61% yesterday. This is why it happened.

NRXP Stock: Why It Substantially Increased

NRx Pharmaceuticals got some good news from the FDA and its shareholders are happy as NRXP stock enjoys a day of impressive gains. The post NRXP Stock Is Soaring Today Thanks to This Big FDA Catalyst appeared first on InvestorPlace.

NRXP Stock Is Soaring Today Thanks to This Big FDA Catalyst

NRX Pharmaceuticals Inc (NASDAQ: NRXP) shares are trading higher by 54.1% at $10.45 after the company announced progress on the worldwide commercial-scale development of ZYESAMI. The company announced that a revised Investigational New Drug module on the manufacturing of ZYESAMI was submitted to the FDA, containing documentation that confirmed Nephron Pharmaceuticals, Inc. is prepared to supply ZYESAMI on a commercial scale.

Why NRX Pharmaceuticals Shares Are Rising

The company announced progress on two fronts for its experimental COVID-19 drug Zyesami.

Why NRx Pharmaceuticals Stock Is Skyrocketing Today

RADNOR, Pa., Oct. 12, 2021 /PRNewswire/ -- NRx Pharmaceuticals (Nasdaq:  NRXP ), today announced that a revised Investigational New Drug module on the manufacturing of ZYESAMI™ (aviptadil) was submitted to the US Food and Drug Administration (FDA), containing documentation that confirmed Nephron Pharmaceuticals, Inc. is prepared to supply ZYESAMI on a commercial scale.

NRx Pharmaceuticals Announces Progress on Worldwide Commercial Scale Development of ZYESAMI™ (aviptadil)

RADNOR, Pa., Sept. 29, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (NASDAQ: NRXP), a clinical stage, biopharmaceutical company today provided a safety update on ZYESAMI™ (aviptadil) which is being tested in the ACTIV-3b Critical Care Phase 3 study sponsored by the National Institutes of Health.

NRx Pharmaceuticals Announces Second Favorable Safety Report for ZYESAMI™ (aviptadil) in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19

NRx Pharmaceuticals Inc (NASDAQ: NRXP) has announced top-line data demonstrating improved outcomes at one year in highly comorbid patients with COVID-19 treated with Zyesami. Between June and September 2020, a trial was conducted at a tertiary care hospital involving patients with Critical COVID-19 whose level of comorbidity excluded them from the Phase 2b/3 trial of Zyesami.

NRx Pharma's COVID-19 Candidate Shows Improved Survival At One Year

RADNOR, Pa., Sept. 27, 2021 /PRNewswire/ -- NRx Pharmaceuticals (Nasdaq: NRXP), a clinical stage, biopharmaceutical company, today announced top line data demonstrating improved outcomes at one year in highly comorbid patients with COVID-19 who were treated with ZYESAMI™.

NRx Pharmaceuticals Announces Improved Survival at One Year in Highly Comorbid COVID-19 Patients Treated with ZYESAMI (aviptadil)

IQVIA (IQV) and NRx are set to work closely to support activities essential for emergency use authorization of ZYESAMI.

IQVIA (IQV) Announces Collaboration With NRx Pharmaceuticals

Iqvia Holdings Inc (NYSE: IQV) has collaborated with NRx Pharmaceuticals Inc (NASDAQ: NRXP) to provide pharmacovigilance services and medical information in preparation for potential regulatory actions. IQVIA will work closely with NRx to support key activities required for emergency use authorization activation for Zyesami in COVID-19, including the pharmacovigilance and medical information programs.

Why Are NRx Pharma Shares Moving Higher On Tuesday Premarket?

IQVIA Hlds

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced a transformative collaboration with NRx Pharmaceuticals (NRx) (Nasdaq: NRXP). NRx is a company dedicated to creating innovative, life-saving treatments and bringing hope to those facing life-altering conditions with no approved disease-modifying therapies or cures. IQVIA is excited to

IQVIA and NRx Pharmaceuticals Collaborate on Potential Medical Support for Novel COVID-19 Treatment

RADNOR, Pa., Sept. 8, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) today announced that NRx's management team will present and host one-on-one investor meetings at the upcoming H.C.

NRx Pharmaceuticals to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

NRx Pharmaceuticals Inc (NASDAQ: NRXP) has announced an additional finding from its Phase 2b/3 trial investigating Zyesami (aviptadil) for critically ill COVID-19 patients with acute respiratory failure.  Previously announced results have focused on survival and recovery from respiratory failure at 60 days and Zyesami's role in preventing the rise in the inflammatory cytokine IL-6 (cytokine storm).

NRx Pharma Stock Is Moving Higher On COVID-19 Candidate Data

RADNOR, Pa., Aug. 30, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) announced an additional finding in its phase 2b/3 clinical trial investigating ZYESAMI™ (aviptadil) for the treatment of patients with acute Respiratory Failure due to Critical COVID-19.

NRx Pharmaceuticals Announces New Finding from ZYESAMI™ (aviptadil) Phase 2b/3 Clinical Trial Demonstrating Clinically Significant Relief from Respiratory Distress in Critical COVID-19

Cardinal Health

NRx Pharmaceuticals Inc (NASDAQ: NRXP) has signed an agreement with Cardinal Health Inc (NYSE: CAH) to provide third-party logistics and distribution of Zyesami upon the potential FDA Emergency Use Authorization (EUA) approval. In May, NRx applied for EUA to the FDA for Zyesami (aviptadil) for critical COVID-19 patients with respiratory failure.

NRx Pharma, Cardinal Health Ink Zyesami Distribution Pact

The stock price of NRx Pharmaceuticals (Nasdaq: NRXP) increased by over 16% during intraday trading. This is why it happened.

NRXP Stock: Over 16% Increase Explanation

RADNOR, Pa., Aug. 26, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) announced today it has signed an agreement with Cardinal Health to provide third party logistics and distribution of ZYESAMI™ upon the potential Emergency Use Authorization (EUA) approval by the US Food and Drug Administration (FDA).

NRx Pharmaceuticals to Work with Cardinal Health to Ensure Efficient Distribution of Potential Therapies

RADNOR, Pa., Aug. 24, 2021 /PRNewswire/ -- NRx Pharmaceuticals (Nasdaq: NRXP), today announced that it has completed its previously announced private placement for the purchase of 2,727,273 shares of common stock.

NRx Pharmaceuticals Announces Closing of $30 Million Private Placement

Investors cheered reports in Israel that COVID-19 vaccine candidate BriLife appears to provide protection for at least six months after a second dose.

Why NRx Pharmaceuticals Stock Vaulted Higher Today

RADNOR, Pa., Aug. 23, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage, biopharmaceutical company noted today reports1 in the Israeli media that participants in the BriLife vaccine trial who received the highest dose vaccine were notified by local health authorities they did not need a third, booster dose of the vaccine as their protection remained high, six months after getting a second dose.

Participants in High Dose BriLife™ Investigational Vaccine Trial for COVID-19 Advised Booster Not Necessary

NRx Pharmaceuticals Inc (NASDAQ: NRXP) stock shed yesterday's gains after announcing a private placement of 2.72 million shares. The purchase price for one share of common stock and one investment option is $11.00.

News for NRX Pharmaceuticals Stock (NRXP)